C. Peng

Publications5
h-index3
Citations78
Highly Influential Citations0
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • N. Kemeny
  • 539 Publications • 31,834 Citations
  • M. D'Angelica
  • 632 Publications • 32,358 Citations
  • W. Jarnagin
  • 781 Publications • 47,827 Citations
  • P. Allen
  • 542 Publications • 30,641 Citations
  • Publications
  • Influence
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis
TLDR
HAI gemcitabine and FUDR is effective to improve DCR of intrahepatic lesions and prolong mOS for patients with nasopharyngeal carcinoma liver metastases, and is associated with a relative low rate of toxicity.
Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy
TLDR
It is reported that the existence of remnant tumor masses due to incomplete RFA (iRFA) is associated with earlier new metastases and poor survival in patients with colorectal cancer liver metastases (CRCLM), and it is demonstrated that iRFA promotes tumor progression and hinders the efficacy of anti-PD-1 therapy.
Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.
TLDR
TRIM52-AS1 sponged miR-514a-5p to facilitate HCC progression through increasing MRPS18A expression and was revealed to be upregulated in HCC tissue samples according to GEPIA database.
Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers
TLDR
Subgroup analysis revealed that patients without EHM, with higher intrahepatic tumor burden and with synchronous liver metastasis benefited more from HAI, and first-line treatment with HAI FUDR plus SCT resulted in higher intraHepatic response and better OS.
949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)